Basket | Login

 
 
 
 

AE adds a new trial to its Clinical Trials Watch

Monday 15 March 2021

Alzheimer Europe continues to develop and improve its Clinical Trials Watch (CTW), an innovative online resource providing up-to-date accessible information on clinical trials currently recruiting participants in a least one European country. The service provides currently information on nine phase II and seven III clinical trials that are investigating drugs for the prevention and treatment of dementia and/or Alzheimer’s disease (AD). In March 2021, the INFRONT-3 trial has been added to the service. The purpose of this Phase II study is to evaluate the safety and efficacy of AL001 in participants at risk for or with frontotemporal dementia due to heterozygous mutations in the progranulin gene. The study is recruiting participants in nine European countries. Further information about the CTW is available on:

http://www.alzheimer- europe.org/Research/Clinical-Trials-Watch

Options